Quantitative High-Throughput Screen Identifies Inhibitors of the Schistosoma mansoni Redox Cascade
2008

Identifying Inhibitors for Schistosomiasis Treatment

Sample size: 71028 publication 10 minutes Evidence: high

Author Information

Author(s): Simeonov Anton, Jadhav Ajit, Sayed Ahmed A., Wang Yuhong, Nelson Michael E., Thomas Craig J., Inglese James, Williams David L., Austin Christopher P.

Primary Institution: NIH Chemical Genomics Center, National Human Genome Research Institute, National Institutes of Health, Bethesda, Maryland, United States of America

Hypothesis

Can we find new inhibitors for the Schistosoma mansoni redox cascade to develop better treatments for schistosomiasis?

Conclusion

The study successfully identified several novel inhibitors of the TGR enzyme in Schistosoma mansoni, which could lead to new treatments for schistosomiasis.

Supporting Evidence

  • The study identified several novel active series that inhibited TGR at various potencies.
  • IC50 values ranged from micromolar to approximately 25 nM.
  • This is the first report of a large-scale HTS to identify lead compounds for a helminthic disease.

Takeaway

Researchers looked for new medicines to help treat a disease called schistosomiasis by testing a lot of different chemicals to see which ones could stop the parasite from surviving.

Methodology

A quantitative high-throughput screening (qHTS) was performed on 71,028 compounds to identify inhibitors of the TGR and Prx enzymes in Schistosoma mansoni.

Limitations

The study focused only on a specific set of compounds and may not cover all potential inhibitors.

Digital Object Identifier (DOI)

10.1371/journal.pntd.0000127

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication